Abattis Bioceuticals Corp (ATT) Director Shuang Xie Sells 50,000 Shares of Stock

Abattis Bioceuticals Corp (CNSX:ATT) Director Shuang Xie sold 50,000 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of C$0.66, for a total transaction of C$33,000.00.

Shuang Xie also recently made the following trade(s):

  • On Tuesday, November 28th, Shuang Xie sold 10,000 shares of Abattis Bioceuticals stock. The stock was sold at an average price of C$0.32, for a total transaction of C$3,200.00.
  • On Thursday, November 23rd, Shuang Xie sold 50,000 shares of Abattis Bioceuticals stock. The stock was sold at an average price of C$0.23, for a total transaction of C$11,500.00.

Abattis Bioceuticals Corp (CNSX:ATT) opened at C$0.61 on Tuesday. Abattis Bioceuticals Corp has a twelve month low of C$0.05 and a twelve month high of C$0.64.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/12/19/abattis-bioceuticals-corp-att-director-shuang-xie-sells-50000-shares-of-stock.html.

About Abattis Bioceuticals

Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets.

Receive News & Ratings for Abattis Bioceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abattis Bioceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply